The study investigated how patient influence on screening adherence affects the cost-effectiveness of various colorectal cancer detection methods in a Chinese population. The researchers created a mathematical model that followed a hypothetical group of 100,000 persons aged 40 to 79 years and compared traditional screening methods (questionnaire, fecal immunochemical test and their combination) with newer non-invasive biomarker-based tests[1][2]. They found that the combination of a questionnaire with a fecal immunochemical test was the most cost-effective strategy, with a cost of $2,413 per year of good-quality life[1][2]. Noninvasive biomarker-based tests have not been cost-effective at current prices, but could become cost-effective if their costs were reduced below $131.7 or if follow-up colonoscopy participation increased to at least 50 to 70 percent[1][2]. Each 10 percent increase in participation in initial screening and follow-up colonoscopy improved economic outcomes in a non-linear fashion[1][2]. Researchers have concluded that improving patient participation in screening is a key factor in increasing the health benefit and cost-effectiveness of colorectal cancer screening programs[1][2].